Developing countries need better antiretroviral drugs

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 1, 2009, Pages 23-24

  Mykén, Nanna ^a   Sundbeck, Boel ^a   Mpumilwa, Godfrey ^b   Andersson, Rune ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Ilembula Lutheran Hospital Ilembula   (Tanzania)

^c SKARABORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DEVELOPING COUNTRY; DRUG COMBINATION; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MIDDLE AGED; TANZANIA; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; STAVUDINE; TANZANIA; TREATMENT OUTCOME;

EID: 67649354856     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109708330119     Document Type: Letter

References (4)

1. Josephson F., Albert J., Flamholc L., et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis. 2007 ; 39: 486-507. (Pubitemid 47017923)
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Jan 29, 2008: 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3. Smyth K., Affandi JS, McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 2007 ; 8: 367-373. (Pubitemid 47163268)
4. Mutimura E., Steward A., Rheeder P., Crowther NJ Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 ; 46: 451-455. (Pubitemid 350098696)